Oslo - Delayed Quote NOK

Navamedic ASA (NAVA.OL)

19.10

-0.05

(-0.26%)

As of 10:20:50 AM GMT+2. Market Open.

Navamedic Q4 and Full Year 2024: Continued growth in a year with investments in new growth initiatives

For the full year 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 531.3, which is 3.8 per cent up from 2023. Adjusted EBITDA amounted to NOK 46.6 million, compared to NOK 51.5 million last year. Gross margin ended at 39.3 per cent, up from 38.9 per cent in 2023.

PR Newswire 2 months ago

NAVA.OL
-0.26%
Navamedic ASA: Amendments to loan agreements with Observe Medical ASA

Navamedic has two loans to Observe Medical ASA, Loan 1 from 27 September 2019, where the current balance, including principal and accrued interest, is NOK 47,775,182 (as of Oct 31st, 2024) and Loan 2 from 6 September 2023, where the current balance, including principal and accrued interest, is NOK 6,083,868 (as of Oct 31st, 2024). Both loans currently have maturity date of 31.1.2025.

PR Newswire 4 months ago

NAVA.OL
-0.26%
Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement

In first half of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 277.2 million, up 12.8 per cent from the corresponding period last year. Adjusted EBITA amounted to NOK 41.1 million compared to NOK 26.3 million in 2023. The milestone payment of NOK 22.7 million following the agreement with Orion Corporation to market and sell Flexilev® and OraFID® in Europe is included.

PR Newswire 7 months ago

NAVA.OL
-0.26%
Navamedic ASA: Minutes of Annual General Meeting

The Annual General Meeting of Navamedic ASA was held today at 09:00 CEST. All items on the agenda were resolved in accordance with the board of directors' proposals and the nomination committee's recommendations. A copy of the minutes from the Annual General Meeting is attached to this notice and will also be made available on the Company's webpage www.navamedic.com.

PR Newswire 10 months ago

NAVA.OL
-0.26%
NAVAO.ST
Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals

Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has received confirmation of an extension of its contract with The Norwegian Hospital Procurement Trust (Sykehusinnkjøp HF) for continued delivery of antibiotics to Norwegian hospitals. The contract runs to 31 January 2027.

PR Newswire 10 months ago

NAVA.OL
-0.26%
Navamedic ASA: Broad launch for Eroxon® in Sweden today

Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies has launched Eroxon® in Sweden. Eroxon® is clinically proven and considered a breakthrough in treatment of erectile dysfunction for men and will be the first non-prescription treatment for erectile dysfunction in the Swedish market.

PR Newswire 11 months ago

NAVA.OL
-0.26%
Navamedic ASA: Invitation to 2024 1st quarter presentation

Navamedic ASA (OSE: Nava) will be presenting its 1st quarter 2024 results on Tuesday, April 30, 2024. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/

PR Newswire 11 months ago

NAVA.OL
-0.26%

Performance Overview

Return	NAVA.OL	OBX Total Return Index (OBX.OL)
YTD	-25.68%	+2.30%
1-Year	-43.66%	+8.35%
3-Year	-36.96%	+16.82%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Navamedic ASA (NAVA.OL)

Navamedic Q4 and Full Year 2024: Continued growth in a year with investments in new growth initiatives

Navamedic ASA: Amendments to loan agreements with Observe Medical ASA

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement

Navamedic ASA: Minutes of Annual General Meeting

Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals

Navamedic ASA: Broad launch for Eroxon® in Sweden today

Navamedic ASA: Invitation to 2024 1st quarter presentation

Performance Overview